Working… Menu

Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France. (CAROLINE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04609800
Recruitment Status : Withdrawn (Unfavorable opinion of IRB/IEC)
First Posted : October 30, 2020
Last Update Posted : December 21, 2020
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : May 10, 2023
Estimated Study Completion Date : May 10, 2023